WGS - GeneDx Holdings Corp.
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
AI-driven health intelligence provider GeneDx attracted a notable insider buy, as recent filings highlight activity amid a volatile year.
PHILADELPHIA, May 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of shareholders who have lost money in their investment in GeneDx stock.
PHILADELPHIA, May 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos and Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of shareholders who have lost money in their investment in GeneDx stock. WHAT'S THIS ABOUT? On May 4, 2026, GeneDx released its financial results for the first quarter of the year.
GeneDx posted Q1 2026 revenue of $102.3 million against consensus estimates near $110 million and reported adjusted EPS of -$0.28 versus the -$0.01 expected -- the stock collapsed approximately 44% in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Shareholders who held GeneDx Holdings Corp. (NASDAQ: WGS) stock lost approximately 44% of their investment value when the company reported Q1 2026 results that fell sharply below Wall Street expectations.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GeneDx (WGS) To Contact Him Directly To Discuss Their Options
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. (NASDAQ: WGS) ("GeneDx Holdings Corp.") concerning potential violations of the federal securities laws. On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the company expected "adjusted net income positive for the full year and each individual quarter" of 2026.
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
GeneDx stock collapsed approximately 44% after Q1 2026 earnings revealed a major revenue miss and a roughly 12% cut to full-year guidance -- weeks after management publicly reaffirmed its outlook GeneDx stock collapsed approximately 44% after Q1 2026 earnings revealed a major revenue miss and a roughly 12% cut to full-year guidance -- weeks after management publicly reaffirmed its outlook
GeneDx Holdings Corp. specializes in advanced exome and genome diagnostic testing, leveraging its proprietary GeneDx Infinity dataset for superior interpretation. Q1 2026 results missed expectations, and guidance for the year was reduced primarily as a result of shifting product mix dynamics and delayed sales cycles. Blended test pricing was adversely impacted by the lower-priced, lower-margin genomic testing segment, which grew faster than anticipated.
NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
GeneDx CFO promised quarterly profitability weeks before the company posted an $8.2 million adjusted loss -- and then cut full-year guidance by approximately 12%. NEW YORK, May 13, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) lost approximately 44% of their share value after Q1 2026 earnings revealed a significant revenue miss and a roughly 12% cut to full-year guidance.
GeneDX (WGS) experienced a 50% stock drop after Q1 misses and FY26 guidance cut, yet volume grew 34% YoY, outpacing internal forecasts. Revenue shortfall was due to mix shift toward lower-ARR genome tests and non-core weakness, not demand or pricing issues. Genome adoption is accelerating, supporting a bullish thesis as payer coverage expands, automation improves, and new channels like general pediatrics ramp.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
PHILADELPHIA, May 12, 2026 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of shareholders who have lost money in their investment in GeneDx stock.
Stock News eBay rejects GameStop bid: eBay (EBAY) declined GameStop's (GME) unsolicited, non-binding acquisition proposal, calling it âneither credible nor at
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.